Related references
Note: Only part of the references are listed.Cardiovascular Safety During and After Use of Phentermine and Topiramate
Mary E. Ritchey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial
Benjamin M. Scirica et al.
CIRCULATION (2019)
A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low-Calorie Diet
Jena Shaw Tronieri et al.
OBESITY (2018)
Cardiovascular Safety of Lorcaserin in Overweigh or Obese Patients
E. A. Bohula et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
Erin A. Bohula et al.
LANCET (2018)
Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study
Steven R. Smith et al.
OBESITY (2017)
Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
A. Blackman et al.
INTERNATIONAL JOURNAL OF OBESITY (2016)
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors A Randomized Clinical Trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants
Mariachiara Di Cesare et al.
LANCET (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
Larissa Shamseer et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
Larissa Shamseer et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
W. Timothy Garvey et al.
DIABETES CARE (2014)
Effects of Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
Priscilla Hollander et al.
DIABETES CARE (2013)
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
T. A. Wadden et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Evaluation of Phentermine and Topiramate versus Phentermine/Topiramate Extended-Release in Obese Adults
Louis J. Aronne et al.
OBESITY (2013)
A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
Caroline M. Apovian et al.
OBESITY (2013)
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
W. Timothy Garvey et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2012)
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A. Astrup et al.
INTERNATIONAL JOURNAL OF OBESITY (2012)
Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
David B. Allison et al.
OBESITY (2012)
Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study
Patrick M. O'Neil et al.
OBESITY (2012)
A Randomized, Double-Blind, Placebo-Controlled Study of an Oral, Extended-Release Formulation of Phentermine/Topiramate for the Treatment of Obstructive Sleep Apnea in Obese Adults
David H. Winslow et al.
SLEEP (2012)
Lorcaserin, A 5-HT2C Receptor Agonist, Reduces Body Weight by Decreasing Energy Intake without Influencing Energy Expenditure
Corby K. Martin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial
Meredith C. Fidler et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
Kishore M. Gadde et al.
LANCET (2011)
Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
Thomas A. Wadden et al.
OBESITY (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Comparison of orlistat treatment and placebo in obese type 2 diabetic patients (Publication with Expression of Concern. See vol. 19, 2018)
Giuseppe Derosa et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Frank L. Greenway et al.
LANCET (2010)
Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management.
Steven R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Arne Astrup et al.
LANCET (2009)
Lorcaserin (APD356), a Selective 5-HT2C Agonist, Reduces Body Weight in Obese Men and Women
Steven R. Smith et al.
OBESITY (2009)
Susruta of India, an unrecognized contributor to the history of exercise physiology
Charles M. Tipton
JOURNAL OF APPLIED PHYSIOLOGY (2008)
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Diana Rucker et al.
BMJ-BRITISH MEDICAL JOURNAL (2007)
Effect of orlistat on cardiovascular disease risk in obese adults
BA Swinburn et al.
DIABETES OBESITY & METABOLISM (2005)
XENical in the prevention of diabetes in obese subjects (XENDOS) study
JS Torgerson et al.
DIABETES CARE (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity
M Krempf et al.
INTERNATIONAL JOURNAL OF OBESITY (2003)
Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet
G Derosa et al.
CLINICAL THERAPEUTICS (2003)
Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension
G Bakris et al.
JOURNAL OF HYPERTENSION (2002)
The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial
M Hanefeld et al.
DIABETES OBESITY & METABOLISM (2002)
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
JM Miles et al.
DIABETES CARE (2002)
Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes - A 1-year randomized controlled trial
DE Kelley et al.
DIABETES CARE (2002)
Treatment of obesity:: need to focus on high risk abdominally obese patients
JP Després et al.
BMJ-BRITISH MEDICAL JOURNAL (2001)
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults
SB Heymsfield et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Orlistat in the long-term treatment of obesity in primary care settings
J Hauptman et al.
ARCHIVES OF FAMILY MEDICINE (2000)
One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor
N Finer et al.
INTERNATIONAL JOURNAL OF OBESITY (2000)
Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity
S Rossner et al.
OBESITY RESEARCH (2000)
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study
F Lindgarde
JOURNAL OF INTERNAL MEDICINE (2000)
Share Paper
